BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 52-Week Low - Time to Sell?

Key Points

• 52-week low: BridgeBio Oncology (BBOT) hit a new 52-week low, trading as low as $8.00 (last $7.9550) and down about 5.6%, with a market cap of $629.7M and a 50-day SMA of $9.20.
• Mixed analyst views but overall positive bias: three Buy ratings and one Sell produce a MarketBeat consensus of "Moderate Buy" with an average price target of $26.00.
• Institutional ownership is substantial (~54.9%), with recent activity including Geode boosting its stake and new positions added by Goldman Sachs and Renaissance Technologies.

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $8.00 and last traded at $7.9550, with a volume of 69323 shares. The stock had previously closed at $8.33.

Analyst Ratings Changes

BBOT has been the subject of a number of research reports. HC Wainwright lifted their target price on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Weiss Ratings initiated coverage on BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They set a "sell (d+)" rating for the company. Stifel Nicolaus started coverage on BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They issued a "buy" rating and a $23.00 price objective on the stock. Finally, Raymond James Financial upgraded BridgeBio Oncology Therapeutics to a "moderate buy" rating in a research report on Friday, January 9th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $26.00.

BridgeBio Oncology Therapeutics Stock Down 5.6%

The business's 50 day simple moving average is $9.20. The firm has a market cap of $629.66 million, a PE ratio of -5.17 and a beta of 0.22.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC boosted its position in shares of BridgeBio Oncology Therapeutics by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 561,987 shares of the company's stock worth $7,039,000 after acquiring an additional 20,385 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $1,185,000. BIT Capital GmbH acquired a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $313,000. CIBC Private Wealth Group LLC purchased a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $63,000. Finally, Renaissance Technologies LLC purchased a new position in BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $930,000. Institutional investors and hedge funds own 54.89% of the company's stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics NASDAQ: BBOT is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.